TLR9 responses of B cells are repressed by intravenous immunoglobulin through the recruitment of phosphatase
One way for intravenous Ig (IVIg) to affect responses of the B cells might be to operate
through their TLR7 and TLR9. We confirm the ability of TLR agonists to induce CD25
expression in B cells. For this to occur, sialylated Fc-gamma of IgG included in the IVIg
preparation are required. As a result, IVIg suppresses TLR-induced production of the
proinflammatory IL-6, but not that of the anti-inflammatory IL-10. That is, IVIg mimics the
effects of the MyD88 inhibitor. Finally, as we previously showed that IVIg induces CD22 to …
through their TLR7 and TLR9. We confirm the ability of TLR agonists to induce CD25
expression in B cells. For this to occur, sialylated Fc-gamma of IgG included in the IVIg
preparation are required. As a result, IVIg suppresses TLR-induced production of the
proinflammatory IL-6, but not that of the anti-inflammatory IL-10. That is, IVIg mimics the
effects of the MyD88 inhibitor. Finally, as we previously showed that IVIg induces CD22 to …
One way for intravenous Ig (IVIg) to affect responses of the B cells might be to operate through their TLR7 and TLR9. We confirm the ability of TLR agonists to induce CD25 expression in B cells. For this to occur, sialylated Fc-gamma of IgG included in the IVIg preparation are required. As a result, IVIg suppresses TLR-induced production of the proinflammatory IL-6, but not that of the anti-inflammatory IL-10. That is, IVIg mimics the effects of the MyD88 inhibitor. Finally, as we previously showed that IVIg induces CD22 to recruit the inhibitory SHP-1, we established that this enzyme was also involved in IVIg-induced inhibition of TLR9 signaling. This is the first report to demonstrate such a mechanism underlying the negative impact of IVIg on B lymphocytes.
Elsevier